SELLAS Life Sciences Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Key Highlights
- ➤SELLAS (SLS) closes $172.5 million underwritten public offering
- ➤13,269,231 shares sold at $13.00 per share
- ➤Underwriters fully exercise option for 1,730,769 additional shares
- ➤New healthcare-focused institutional investors participate in offering
NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the closing of its previously announced underwritten public offering of 13,269,231 shares of its common stock at a public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,730,769 additional shares of common stock. The aggregate gross proceeds to SELLAS from this offering were $172.5 million before deducting underwriting discounts and commissions and offering expenses. Investors in the offering included new healthcare-focused institutional investors.
J.P. Morgan and TD Cowen acted as the lead book-running managers for the offering. Mizuho also acted as a book-running manager for the offering. A.G.P./Alliance Global Partners and Maxim Group LLC acted as lead managers for the offering.
Get started
Create a free account to read the full story.
